Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Aripiprazole tablet, 10 mg Clear all

Conditions: Behavioral Symptoms, Autistic Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 31
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 28 more

Conditions: Device Latency
Interventions: Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application; Drug · Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Schizophrenia
Interventions: aripiprazole IM depot, aripiprazole tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Cerritos, California • Garden Grove, California • Glendale, California + 4 more

Conditions: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, Ingestible Event Marker (IEM); Drug · Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 12
States / cities: Cerritos, California • Garden Grove, California • Long Beach, California + 9 more

Conditions: Autistic Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 9
States / cities: Boca Raton, Florida • Atlanta, Georgia • Louisville, Kentucky + 6 more

Conditions: Schizophrenia, Bipolar Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 50
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 47 more

Conditions: Autism
Interventions: Aripiprazole, Placebos; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 5 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Healthy
Interventions: Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline; Drug
Lead sponsor: Centre for Addiction and Mental Health; Other
Eligibility: 60 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • St Louis, Missouri • New York, New York

Conditions: Schizophrenia
Interventions: Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 39
States / cities: Cerritos, California • Escondido, California • Garden Grove, California + 31 more

Conditions: Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • St Louis, Missouri • New York, New York + 1 more

Conditions: Bipolar Disorder
Interventions: Lamotrigine + Aripiprazole, Lamotrigine + Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 55 more

Conditions: Autistic Disorder, Behavioral Symptoms
Interventions: Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 55
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more

Conditions: Schizophrenia
Interventions: LY2140023, Placebo, Standard of Care; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Blinded capsule; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Cerritos, California • Costa Mesa, California • Irvine, California + 21 more

Conditions: Healthy
Interventions: Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions: Aripiprazole + IEM (Ingestible Event Marker); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more

Conditions: Tourette's Disorder, Tic Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 55
States / cities: Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 52 more

Conditions: Schizophrenia
Interventions: Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg, Placebo tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 50 more

Conditions: Bipolar Disorder
Interventions: aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania • Austin, Texas • Bellaire, Texas + 1 more

Conditions: Schizophrenia
Interventions: LY2140023, aripiprazole, olanzapine, risperidone; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more

Conditions: Schizophrenia
Interventions: Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: Tourette's Disorder (TD)
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Anaheim, California • Riverside, California • Santa Ana, California + 30 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole, placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 53
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more

Search by objective public record fields.

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

Aripiprazole Open-Label, Safety and Tolerability Study

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

Aripiprazole and Effexor XR Drug Interaction Study

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Aripiprazole and Lexapro Drug Interaction Study

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Aripiprazole in Adolescents With Schizophrenia

Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder

Aripiprazole in Children and Adolescents With Bipolar I Disorder